Quantcast

Latest rheumatoid arthritis Stories

2014-10-29 16:28:36

Payers Employ a Variety of Cost-Control Measures to Manage the Utilization of Premium-Priced RA Agents, According to Findings from Decision Resources Group BURLINGTON, Mass., Oct. 29, 2014 /PRNewswire/ -- Decision Resources Group finds that although 80 percent of surveyed rheumatologists currently prescribe Pfizer's Xeljanz for the treatment of rheumatoid arthritis (RA), it is usually used in later lines of therapy. Physicians most frequently cite limited formulary coverage and reimbursement...

2014-10-29 12:30:01

New endurance program unites psoriatic disease community and cycling enthusiasts to find a cure PORTLAND, Ore., Oct. 29, 2014 /PRNewswire-USNewswire/ -- Cyclists with psoriasis and psoriatic arthritis and the people who love them now have a new way to find a cure with the National Psoriasis Foundation Team NPF Cycle program, launching today on World Psoriasis Day. National Psoriasis Foundation Team NPF Cycle, presented by Novartis Pharmaceuticals Corporation, is an endurance...

2014-10-28 23:02:36

Achieve Clinical Research recently opened up a new clinical trial, and they are looking to enroll individuals who are suffering from clinically relevant arthritis pain. Adults who are experiencing osteoarthritis symptoms of the knee could qualify. Birmingham, AL (PRWEB) October 28, 2014 *To learn more about this osteoarthritis (OA) clinical trial in Birmingham, AL, please check out Achieve Clinical Research on the web (http://www.achieveclinical.com) or contact them directly at (205)...

2014-10-28 16:27:34

Focusing development on rare autoimmune disorder IgG4-related disease (IgG4-RD) MONROVIA, Calif., Oct. 28, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that it has regained all development and commercial rights to XmAb(®)5871 by seeking and obtaining a termination of the prior option and...

2014-10-28 08:37:02

TARRYTOWN, N.Y., Oct. 28, 2014 /PRNewswire/ -- Araim Pharmaceuticals, a privately held company engaged in developing novel treatments for devastating injuries and chronic diseases underserved by current therapies, today announced a Fast Track Designation from the FDA for its lead compound ARA290, for treatment of Sarcoidosis-associated Small Fiber Neuropathy (SFN). http://photos.prnewswire.com/prnvar/20141023/154567LOGO Small nerve fiber loss and damage causes autonomic and sensory...

2014-10-22 12:30:14

Presentations examine certain demographic and clinical disease characteristics that may be indicative of Cimzia® treatment response and remission for moderate to severe Crohn's disease ATLANTA, Oct. 22, 2014 /PRNewswire/ -- UCB, a global biopharmaceutical company focusing on CNS and immunology treatment and research, is sponsoring several data presentations on Cimzia(®) (certolizumab pegol) at the American College of Gastroenterology's (ACG) 2014 Annual Scientific Meeting in Philadelphia,...

2014-10-21 23:15:35

Ongoing and Recent Evidence Shows RA Patients Who Supplement Methotrexate With Folate Therapy Have Better Outcomes, According To Makers of EnLyte With Delta Folate. Sunset, LA (PRWEB) October 21, 2014 Over one million people in the U.S. suffer from rheumatoid arthritis (RA), an autoimmune disease marked by pain, swelling, and stiffness in the joints. The most common first line treatment for RA is methotrexate, a prescription medication belonging to the class of drugs knows as DMARDS....

2014-10-20 12:30:16

DALLAS, October 20, 2014 /PRNewswire/ -- ReportsnReports.com adds Gouty Arthritis (Gout) - Pipeline Review, H2 2014 market research report as well as EpiCast Report: Gout - Epidemiology Forecast to 2023 to the pharmaceuticals segment of its online library. The Gouty Arthritis (Gout) - Pipeline Review, H2 2014 [http://www.reportsnreports.com/reports/311359-gouty-arthritis-gout-pipeline-review-h2-2014.html ] market research report provides comprehensive information on...

2014-10-17 23:02:09

A California man filed a class action lawsuit against Immunex and Caremark CVS alleging that the pharmacy fails to properly refrigerate best-selling drug Enbrel when filling a mail order Caremark prescription. As a result, thousands of seniors and disabled persons may be using Enbrel that, based on the manufacturer’s own guidelines, should not be used and should be discarded immediately; the plaintiff further alleges that the unapproved Enbrel is ineffective in treating his arthritis...

2014-10-13 08:27:39

- HS is a painful, chronic inflammatory skin disease that impacts approximately 1 percent of the adult population worldwide with no approved treatment options available[1],[2],[3] AMSTERDAM, Oct. 13, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced new results from PIONEER II, a pivotal Phase 3 study, demonstrating the effect of HUMIRA® (adalimumab) in reducing common clinical signs and symptoms in moderate-to-severe hidradenitis suppurativa (HS), specifically the number of abscesses and...


Word of the Day
barghest
  • A goblin in English folklore, often appearing in the shape of a large dog and believed to portend imminent death or misfortune.
  • A ghost, wraith, hobgoblin, elf, or spirit.
The origin of 'barghest' is not known, but it may be from perhaps burh-ghest, town-ghost, or German Berg-geist (mountain spirit) or Bär-geist (bear-spirit).
Related